FIELD: medicine.
SUBSTANCE: this group of inventions refers to medicine and genetic engineering. Disclosed are methods of producing modified killer (NK) cell lines with knockout PD-1 gene or, in other embodiments, with knockout PD-1 gene and constitutive high expression of Fas-ligand, or with knockout PD-1 gene and constitutive high expression of TRAIL. What is also described is a method of selecting modified NK cells with knockout PD-1 gene, which is carried out using a selective zeocin marker. What is also presented is using the obtained cell lines in order to induce apoptosis or lysis of mammalian cancer cells.
EFFECT: present group of inventions provides high output of modified NK cell lines exhibiting high tumour cell growth inhibition activity.
14 cl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| INSERTION OF TARGET GENE FOR IMPROVED CELLULAR IMMUNOTHERAPY | 2017 |
|
RU2824204C2 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
| EXPRESSION PLASMID VECTORS FOR EXPRESSION OF TNFR1-Fc ACTIVE FORM, AND METHODS FOR RECOMBINANT PROTEINS PRODUCTION | 2016 |
|
RU2625010C1 |
| METHOD FOR CREATION OF T-CELLS SUITABLE FOR ALLOGENEIC TRANSPLANTATION | 2015 |
|
RU2752933C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| MODIFIED IMMUNOREGULATORY ELEMENT AND IMMUNITY CHANGE BY THIS ELEMENT | 2017 |
|
RU2767206C2 |
| IMPROVED IMMUNE CELLS WITH DOUBLE shRNA AND COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2793922C2 |
